CD3单克隆抗体激活细胞用于中、晚期癌肿治疗的初步观察

本文采用正常人外周血单个核细胞，经加用ＣＤ３单克隆抗体，辅以少量ＩＬ－２共同培养，制备ＣＤ３单抗激活杀伤（ＣＤ３ＡＫ）细胞。通过对４５例中、晚期癌肿患者临床试用，初步观察并分析了该项治疗临床疗效及意义。结果表明ＣＤ３ＡＫ细胞治疗的临床总有效率为５３．３％；不同肿瘤间有效率无明显差异；细胞输注总量的增加及多次输注者，临床有效率明显提高；接受该项治疗患者，机体ＮＫ细胞活性增强，ｓＩＬ－２Ｒ浓度下降，而治疗前后ｍＩＬ－２Ｒ、ＴＮＦ水平未见明显差异。

The Primary Observation on the Treatment for Patients with Middle and Advanced Cancers by Infusing CD3AK Cells

The clinical effect and significance of the treatment with CD3AK(CD3 McAbactivated killer cells) in 45 cases with middle-late cancers were investigated. The CD3AK cells were porducted by induced normal human PBMC with CD3 McAb and IL2.The results showed that the total effective rate was 53.3% after CD3AK cells treatment with no significant difference among several tumors.It was found that theclinically effective rate was raised with increasing quantity and frequency of CD3AK cells infused.After the ti.eatment with CD3AK cells the activity of NK cells ontumors increased.and the level of sIL-2R decreased,while no significant change wasfound in the level of mIL-2R expressed and the serum concentration of TNF.